Synaptogenix, Inc. (NASDAQ:SNPX) Sees Large Decrease in Short Interest

Synaptogenix, Inc. (NASDAQ:SNPX) was the target of a large drop in short interest in May. As of May 31st, there was short interest totalling 21,200 shares, a drop of 18.5% from the May 15th total of 26,000 shares. Approximately 1.8% of the company’s stock are sold short. Based on an average trading volume of 47,300 shares, the short-interest ratio is currently 0.4 days.

Synaptogenix Price Performance

SNPX traded down $0.05 during mid-day trading on Monday, reaching $4.56. 6,133 shares of the stock were exchanged, compared to its average volume of 42,662. The company has a 50 day moving average price of $4.60 and a two-hundred day moving average price of $5.21. Synaptogenix has a 1 year low of $3.53 and a 1 year high of $47.00.

Synaptogenix (NASDAQ:SNPX) last released its quarterly earnings results on Wednesday, May 15th. The company reported ($0.41) earnings per share for the quarter.

About Synaptogenix

Synaptogenix, Inc operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. The company focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. It also evaluates therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease.